Funding

ICER’s mission is funded through a diverse combination of sources as grants, contracts and unrestricted gifts; funding is not accepted from manufacturers or private insurers to perform reviews of specific technologies. ICER’s core programs, CTAF, Midwest CEPAC, and New England CEPAC, receive the vast majority of their funding from private foundations.  Since June 2016, ICER has received contributions from the following sources:
  • Bayer
  • Blue Cross Blue Shield of Massachusetts
  • Blue Shield of California Foundation
  • California Health Care Foundation
  • Decision Resources
  • Guggenheim Securities
  • Harvard Pilgrim Health Care
  • Kaiser Permanente National Community Benefit Fund at the East Bay Community Foundation
  • Laura and John Arnold Foundation
  • NESCSO/University of Massachusetts
  • Partners Healthcare
  • University of New Hampshire
  • Washington State Health Care Authority
ICER also receives support from pharmaceutical and health insurance companies for the annual ICER Policy Summit, Evidence Dialogue webinars, and other membership activities.  Current members include:
  • Aetna
  • America’s Health Insurance Plans (AHIP)
  • Anthem
  • AstraZeneca
  • Blue Shield of California
  • CVS Caremark
  • Express Scripts
  • Genentech
  • GlaxoSmithKline
  • Harvard Pilgrim Health Care
  • Health Care Service Corporation (HCSC)
  • Johnson & Johnson
  • Kaiser Permanente
  • Merck & Co.
  • National Pharmaceutical Council
  • OmedaRx
  • Premera Blue Cross
  • Prime Therapeutics
  • Sanofi
  • Spark Therapeutics
  • United HealthCare